| Outcome Measures: |
Primary: 1-Hour Change in Postprandial Plasma Glucose (PPG), Change was calculated as the PPG value at 1 hour minus the PPG value at baseline (time -2 minutes) during meal test, 6th week of therapy | Secondary: 2-Hour Change in Postprandial Plasma Glucose (PPG), Change was calculated as the value at 2 hour minus the value at baseline during meal test, 6th week of therapy|Percentage of Time Spent Between Below 70 mg/dL, Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each), Weeks 1 through 6, Weeks 8 through 13|Percentage of Time Spent Between 70 mg/dL and 180 mg/dL, Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each), Weeks 1 through 6, Weeks 8 through 13|Percentage of Time Spent Above 200 mg/dL, Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each), Weeks 1 through 6, Weeks 8 through 13|Percentage of Time Spent in Hypoglycemia (40 mg/dL - 54 mg/dL), Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each), Weeks 1 through 6, Weeks 8 through 13|Percentage of Time Spent in Severe Hypoglycemia (> 40 mg/dL), Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each), Weeks 1 through 6, Weeks 8 through 13|1,5 Anhydroglucitol Levels, 1,5 anhydroglucitol levels were measured on the 6th week of each therapy, Week 6, Week 13|Fructosamine Levels, Cumulative glycemic control expressed in fructosamine levels (micromol/Liter) were measured on the 6th week of each therapy, Week 6, Week 13|HbA1c, Cumulative glycemic control expressed in HbA1c% measured on the 6th week of each therapy, Week 6, Week 13|Insulin Use - Change in Daily Dose, Change was calculated as the value on the last day of therapy minus the value on the 1st day of therapy in each period, Weeks 1 through 6, Weeks 8 through 13|Insulin Use - Bolus, Change in %bolus insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period, Weeks 1 through 6, Weeks 8 through 13|Insulin Use - Basal, Change in %basal insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period, Weeks 1 through 6, Weeks 8 through 13|Insulin Use - Automatic Basal Insulin, Average amount per day (units) calculated for each participant under each therapy, Weeks 1 through 6, Weeks 8 through 13|Insulin Pump - Active Insulin Time, Average time per day (hours) calculated for each participant under each therapy, Weeks 1 through 6, Weeks 8 through 13|Insulin Pump - Auto Mode, Percentage of time spent in auto-mode after calibration under each therapy, Weeks 3 through 6, Weeks 10 through 13|Insulin Pump - Manual Mode, Percentage of time spent in manual-mode after calibration under each therapy, Weeks 3 through 6, Weeks 10 through 13|Change in Carbohydrate Ratio, Change was calculated as the carbohydrate ratio on the last day of therapy minus the carbohydrate ratio on the 1st day of therapy in each period, Weeks 1 through 6, Weeks 8 through 13|Infusion Site Reactions, Number of Infusion site reactions reported by patient, 14 week treatment period|Pump Occlusions, Number of Occlusion events reported by patient, 14 week treatment period
|
